EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Relationship of the revised anticholinergic drug scale with cultured cell‐based serum anticholinergic activity and cognitive measures in older adults with mild cognitive impairment or remitted depression

Ryan M Carnahan iD, Susmita Chandramouleeshwaran iD, Naba Ahsan iD, Roger Raymond iD, Jose N Nobrega iD, Wei Wang iD, Corinne E Fischer iD, Alastair J Flint iD, Nathan Herrmann iD, Sanjeev Kumar iD, Krista L Lanctôt iD, Linda Mah iD und 3 weitere

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Ryan M Carnahan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, The University of Iowa College of Public Health, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Cholinergic Antagonists, Major Depressive Disorder, Cognition. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centre for Addiction and Mental Health Discovery Fund, Canada Brain Research Fund of Brain Canada, Health Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The Anticholinergic Drug Scale (ADS) is a commonly used measure of anticholinergic exposure. This study describes an expanded and revised version of the ADS (rADS) and its relationship with cultured cell‐based serum anticholinergic activity (cSAA) and cognitive measures. Study Participants Adults aged 60 years and older with mild cognitive impairment (MCI), remitted major depressive disorder (rMDD), or both, participate in the Prevention of Alzheimer's Dementia with Cognitive Remediation plus Transcranial Direct Current Stimulation (PACt‐MD) study. Study Design Cross‐sectional investigation of data from the PACt‐MD study. Measures The rADS includes ratings for 1047 distinct products, about twice as many as the originally published scale; previously published ratings were revised for 40 drugs. Total rADS scores were calculated as sums of ratings of all drugs taken by participants; cSAA was measured in the participants' sera; cognitive performance included measures of executive function, language, processing speed, verbal memory, visuospatial memory, working memory, and an overall composite score. Statistical Analysis The relationship between rADS total scores and cSAA was examined using a Spearman rank correlation coefficient. Relationships between rADS total scores and cognitive performance measures were explored in multivariable linear regression models.

Results

The sample included 310 participants (mean [standard deviation] age: 72 (6) years; 61.6% were women, and 81.6% had MCI [with or without rMDD]). Total rADS scores were positively correlated with cSAA (Spearman's correlation coefficient: 0.178, p = 0.0016). Total rADS scores were not significantly associated with cognitive performance.

Conclusions

The revised scale is recommended as a replacement for the original ADS since it includes ratings for more drugs and was significantly, albeit weakly, associated with cSAA, similar to previous findings using the original ADS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionCholinergic AntagonistsMajor Depressive DisorderCognitionHumansFemaleAgedMaleCross-Sectional StudiesMiddle AgedNeuropsychological TestsCells, CulturedAged, 80 and over

Stichwörter der Autor:innen

anticholinergic medicationscognitiondepressionmild cognitive impairmentmuscarinic antagonistspolypharmacy

Substanzen

Cholinergic Antagonists

Autor:innen und Institutionen

  • Department of Epidemiology, The University of Iowa College of Public Health, Iowa City, Iowa, USA.
  • Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada.
  • Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  • Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.
  • Toronto Dementia Research Alliance, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Ryan M Carnahan, Susmita Chandramouleeshwaran, Naba Ahsan, Roger Raymond, Jose N Nobrega, Wei Wang, Corinne E Fischer, Alastair J Flint, Nathan Herrmann, Sanjeev Kumar, Krista L Lanctôt, Linda Mah, Benoit H Mulsant, Bruce G Pollock, Tarek K Rajji

Förderung

  • Centre for Addiction and Mental Health Discovery Fund
  • Canada Brain Research Fund of Brain Canada
  • Health Canada
  • The Chagnon Family
  • Centre for Addiction and Mental Health Foundation
  • Fondation Brain Canada

Zitieren

APA

Carnahan, R. M., Chandramouleeshwaran, S., Ahsan, N., Raymond, R., Nobrega, J. N., Wang, W., Fischer, C. E., Flint, A. J., Herrmann, N., Kumar, S., Lanctôt, K. L., Mah, L., Mulsant, B. H., Pollock, B. G., & Rajji, T. K. (2025). Relationship of the revised anticholinergic drug scale with cultured cell‐based serum anticholinergic activity and cognitive measures in older adults with mild cognitive impairment or remitted depression. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70022

Vancouver

Carnahan RM, Chandramouleeshwaran S, Ahsan N, Raymond R, Nobrega JN, Wang W, et al. Relationship of the revised anticholinergic drug scale with cultured cell‐based serum anticholinergic activity and cognitive measures in older adults with mild cognitive impairment or remitted depression. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70022

BibTeX
@article{Carnahan2025,
  author = {Carnahan, Ryan M and Chandramouleeshwaran, Susmita and Ahsan, Naba and Raymond, Roger and Nobrega, Jose N and Wang, Wei and Fischer, Corinne E and Flint, Alastair J and Herrmann, Nathan and Kumar, Sanjeev and Lanctôt, Krista L and Mah, Linda and Mulsant, Benoit H and Pollock, Bruce G and Rajji, Tarek K},
  title = {Relationship of the revised anticholinergic drug scale with cultured cell‐based serum anticholinergic activity and cognitive measures in older adults with mild cognitive impairment or remitted depression},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70022}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche